SLNO

Current Thesis

Pure merger-arb, closed story. NBIX announced definitive $53.00/share cash acquisition on 2026-04-06 ($2.9B equity value). All five sell-side desks collapsed PTs to exactly $53 between 2026-04-06 and 2026-04-17 (Cantor, Wolfe, TD Cowen, HC Wainwright, Wells Fargo) — Street is pricing deal price as ceiling, zero narrative optionality left. Today (2026-04-20) we are T+14 days post-announcement; any tradeable edge now is spread-scalping, not narrative-momentum. This is NOT our playbook.

Bull Case

• Strategic buyer, clean fit: NBIX product acquisition (DCCR/VYKAT already FDA-approved for Prader-Willi). FT leak 2026-04-06 framed as NBIX "tapping high-growth rare disease market" — strategic, not opportunistic. Lower break probability.
• Low antitrust surface: NBIX has no overlapping PWS franchise; single-indication orphan drug → narrow HSR review. Early-termination notice is plausible inside 30 days of filing.
• Unanimous $53 PT collapse across 5 desks in 8 trading days (2026-04-06 → 2026-04-17) signals Street consensus that break risk is <10%. That's a real signal, not noise.
• Whale alerts 2026-04-07 (tagged in "9 Health Care Stocks With Whale Alerts") consistent with arb funds sizing spread, not hedging a break.
• Trading halt 2026-04-06 06:55 ET resolved cleanly with the NBIX announcement — no competing process, no overhang.

Bear Case

• Spread IS the entire P&L. At ~$52.50 print with 5–8 months to close, gross return is sub-1% — under Treasuries. For a narrative-momentum book this is capital-parked-for-nothing.
• Asymmetry is horrible: +1–2% upside vs -35% downside on break (pre-deal range implied ~$30–35). Textbook negative-convexity trade.
• Zero topping-bid optionality: $2.9B already stretches for single-asset rare-disease co; no logical counter-bidder with PWS franchise exists.
• MAC tail: VYKAT post-marketing issue, CMC surprise, or label action could give NBIX an out. Low probability, catastrophic impact.
• Wrong archetype for our book. Binary-catalyst merger arb is not what this system edges. We trade narrative velocity, not 80bps to deal close.

Setup & Price Structure

No live price tape supplied. Structure is a flat line pinned near $52.50–$53.00, not a trending chart. Hard ceiling is deal price $53.00; analyst PT cluster sits on exactly $53.00 (5 desks, unanimous). Pre-announcement standalone was high-$30s implied by 2026-04-06 "big stocks moving higher" gap. Only actionable signal from the chart is a dislocation: any print <$52.50 implies market is pricing break risk and is the lone re-evaluation trigger. No 20-EMA / RSI / breakout framework applies — arb lines don't trend.

Catalyst Calendar (next 30 days)

• ~2026-05-05 to 2026-05-09 (est.): SLNO Q1 2026 10-Q filing window. Last standalone financials before close. Immaterial to arb UNLESS it surfaces MAC-triggering data (VYKAT demand, AE signal).
• ~2026-05-06 (est.): HSR 30-day waiting period expiration (assumes filing ~2026-04-06). Early-termination notice would compress spread toward $53 instantly — primary spread-compression catalyst.
• ~2026-05-06 to 2026-05-20 (est.): S-4/proxy filing and record date for shareholder vote. 30–45 days post-announcement is typical.
• No earnings-call catalyst: SLNO will not host standalone guidance through close — removes a common narrative ignition path.

What Would Change Our Mind

1. SLNO prints <$51.00 intraday on no news → market pricing >15% break probability → the arb becomes interesting risk/reward. This is the ONLY chart-level entry trigger.
2. Any 8-K referencing FTC second request, timing agreement, or HSR extension → close slips 3–6 months, annualized return halves → skip / exit.
3. NBIX 8-K or FT/Bloomberg leak citing MAC, renegotiation, or price cut → immediate exit; SLNO re-rates to pre-deal ~$30–35.
4. Topping bid rumor from a credible counter-bidder with PWS franchise (low probability, high impact) → this would flip back into a narrative trade; reassess.
5. Q1 10-Q reveals VYKAT demand miss or safety signal → raises break probability materially; skip.

Correlation Notes

• NBIX (acquirer): weakly inverse short-term; NBIX strength supports deal certainty, weakness can re-open renegotiation risk. Not tradeable as a pair.
• Rare-disease M&A tape: Apellis/Biogen deal referenced 2026-04-06 in the same news cycle — signals broad strategic-pharma appetite for rare-disease assets, which REDUCES SLNO break risk at the margin but has no direct P&L linkage post-announcement.
• Biotech XBI/IBB beta: effectively zero until deal closes. SLNO trades as a bond with a tail, not an equity.
• Operator takeaway: SLNO offers no narrative-momentum edge from here. Status should stay DORMANT unless the spread dislocates below [entry redacted] Not a skip for lack of quality — a skip for wrong archetype.